Bod Australia Limited provide the following statistical summary from its Phase 1 cannabidiol (CBD) pharmacokinetic (PK) study. The PK study, undertaken as part of a number of elements within Bod's Schedule 3 (pharmacist only) project, forms a critical and required step for the Company's dossier submission to the TGA (Therapeutic Goods Association). Bod's ongoing Phase IIb clinical trial underpins the Company's drive to develop a new Schedule 3 (pharmacist only) CBD product to be made available to the Australian market.

This supports Bod's strategy of consistently selling products through SAS-B channels since 2018 which has allowed the Company to build a strong foothold in the market. The PK study consisted of 3 oral treatment arms delivered as a single dose in a crossover design in 14 healthy subjects between 18-50 years old, each equating to 100mg CBD per day: Bod ECS BioAbsorb Soft Gel Capsule; Epidyolex Oil (a TGA & FDA-approved, plant-derived, purified prescription cannabidiol); CBD isolate in MCT oil (a supplement made from a structure of fat termed medium-chain triglycerides). Statistical analysis received on the study supports the potential for Bod's unique ECS BioAbsorb Soft Gel to be the benchmark delivery format for the over the counter CBD market.

The below outcomes were reported in relation to the trial's primary and secondary endpoints: Bod ECS BioAbsorb Softgel showed over 20% greater concentration of CBD in the blood than Epidyolex; Bod ECS BioAbsorb Softgel showed over 400% greater concentration of CBD in the blood than CBD Isolate Oil solution; The maximum concentration of CBD after a single oral administration of Bod ECS BioAbsorb Softgel was over 60% greater than Epidyolex; The maximum concentration of CBD after a single oral administration of Bod ECS BioAbsorb Softgel was 600% more than CBD Oil solution; The time to reach the maximum concentration of CBD after single oral administration of Bod ECS BioAbsorb Softgel was twice as fast as Epidyolex and five times faster than CBD Oil solution.